| Trial ID: | L6985 |
| Source ID: | NCT01710371
|
| Associated Drug: |
18f-Av-133
|
| Title: |
Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: 18F-AV-133|DRUG: 10% Arginine Hydrochloride-R-Gene 10
|
| Outcome Measures: |
Primary: Optimal PET-determined mean pancreatic Binding Potential of 18F-AV-133, PET visit 1|Optimal PET-determined mean pancreatic Standardized Uptake Value (SUV) of 18F-AV-133, PET visit 1|Optimal PET-determined mean pancreatic Volume of Distribution (VT) of 18F-AV-133, PET visit 1 |
|
| Sponsor/Collaborators: |
Sponsor: Avid Radiopharmaceuticals | Collaborators: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2012-12
|
| Completion Date: |
2015-09
|
| Results First Posted: |
|
| Last Update Posted: |
2015-11-13
|
| Locations: |
Research Site, New Haven, Connecticut, 06511, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01710371
|
